A
Alcista
Alcista · 25%ECOR
$6.71
Precio del escenario
$8.800
+0.419 (+4.76%)Al cierre
Loading chart…
- Máximo
- 9.000
- Apertura
- 8.120
- Precio medio ponderado por volumen
- 8.56
- Volumen
- 185.65K
- Capitalización
- 41.50M
- Mínimo
- 7.895
- Importe
- 1.59M
- EV/EBITDA, TTM
- -5.64
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
Análisis de IA of electroCore, Inc. (ECOR)
VenderCurrently, electroCore, Inc. (ECOR) is not a good buy. The stock is trading at $7.16, which is significantly below its 52-week high of $12.70, indicating a potential for further downside. Additionally, the RSI is at 33.004, suggesting that the stock is oversold, but this could also mean continued weakness in the short term. The forward P/E ratio is extremely high at 384.6154, reflecting investor skepticism about future earnings growth, while insider selling has increased by 666.36% over the last month, indicating a lack of confidence from those closest to the company. The main risk is the negative earnings trend, with an EPS estimate of -0.26 for the next earnings report, which could further pressure the stock price.
Recomendaciones de analistas (2)
+70.45% de potencial alcista
Comprar
2 Comprar
0 Mantener
0 Vender
Actual: 8.80
Mínimo
12.00
Promedio
15.00
Máximo
18.00
Ladenburg
Comprar
—
2026-11-05
Ladenburg
2026-11-05
Precio objetivo
—
Comprar
Ladenburg
Comprar
$22
2026-05-07
Ladenburg
2026-05-07
Precio objetivo
$22
Comprar
H.C. Wainwright
Comprar
$18
2026-01-26
H.C. Wainwright
2026-01-26
Precio objetivo
$18
Comprar
Ladenburg Thalmann
Compra fuerte
$26
2025-03-13
Ladenburg Thalmann
2025-03-13
Precio objetivo
$26
Compra fuerte
HC Wainwright & Co.
Compra fuerte
$25
2025-03-13
HC Wainwright & Co.
2025-03-13
Precio objetivo
$25
Compra fuerte
Métricas de valoración
El PER previsto actual de electroCore, Inc. (ECOR) es 384.62, frente a su media de 5 años de 63.56.
Escenarios de precio de Alphio AI para ECOR
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con ECOR en cartera
Cronología de eventos
Noticias
9.010-28NewsfilterelectroCore Submits 510(k) for Quell Device to Treat CIPN
2.009-07Yahoo FinanceEcora Announces Change of Registered Office Address
9.509-04Yahoo FinanceEcora Reports 75% Increase in H1 2026 Portfolio Contribution
9.509-02Yahoo FinanceEcora Royalties Reports Strong Half-Year Results for 2026
2.005-27NASDAQ.COMMultiple Companies See Significant Stock Price Gains
Preguntas frecuentes sobre ECOR, respondidas por Alphio AI
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).
Currently, electroCore, Inc. (ECOR) is not a good buy. The stock is trading at $7.16, which is significantly below its 52-week high of $12.70, indicating a potential for further downside. Additionally, the RSI is at 33.004, suggesting that the stock is oversold, but this could also mean continued weakness in the short term. The forward P/E ratio is extremely high at 384.6154, reflecting investor skepticism about future earnings growth, while insider selling has increased by 666.36% over the last month, indicating a lack of confidence from those closest to the company. The main risk is the negative earnings trend, with an EPS estimate of -0.26 for the next earnings report, which could further pressure the stock price.
2 analysts cover ECOR: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 15.00.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.